Vir Biotechnology Inc Asset Resilience Ratio
Vir Biotechnology Inc asset resilience ratio. Vir Biotechnology Inc (VIR) has an Asset Resilience Ratio of 20.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Vir Biotechnology Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vir Biotechnology Inc (2017–2025)
Asset resilience ratio of Vir Biotechnology Inc from 2017 to 2025. This chart shows how Vir Biotechnology Inc's Asset Resilience Ratio has changed over time. Read VIR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vir Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VIR total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $249.86 Million | 20.57% |
| Total Liquid Assets | $249.86 Million | 20.57% |
Asset Resilience Insights
- Good Liquidity Position: Vir Biotechnology Inc maintains a healthy 20.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Vir Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Vir Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Vir Biotechnology Inc Asset Resilience Ratio by Year (2017–2025)
Vir Biotechnology Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Vir Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.81% | $228.75 Million | $1.00 Billion | -25.97pp |
| 2024-12-31 | 48.78% | $682.40 Million | $1.40 Billion | -17.96pp |
| 2023-12-31 | 66.74% | $1.28 Billion | $1.92 Billion | +11.31pp |
| 2022-12-31 | 55.44% | $1.55 Billion | $2.80 Billion | +37.00pp |
| 2021-12-31 | 18.44% | $360.33 Million | $1.95 Billion | -14.25pp |
| 2020-12-31 | 32.68% | $300.29 Million | $918.76 Million | -20.84pp |
| 2019-12-31 | 53.53% | $274.10 Million | $512.07 Million | +26.99pp |
| 2018-12-31 | 26.54% | $50.84 Million | $191.60 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $251.57 Million | -- |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more